SATSUMA PHARMACEUTICALS, INC. Inactive Instrument
Satsuma Pharmaceuticals, Inc. Share Price
Equities
STSA
US80405P1075
Biotechnology & Medical Research
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 08/23/08 |
Mic Iwashima
COO | Chief Operating Officer | 46 | 01/17/01 |
| Chief Tech/Sci/R&D Officer | 63 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 08/23/08 |
| Director/Board Member | 64 | 08/23/08 | |
Ken Takanashi
BRD | Director/Board Member | 59 | 01/16/01 |
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
